Where We Fit
Predictive Oncology is uniquely positioned to serve the four major segments that drive drug discovery: Clinical Research, Academic Research, Pharmaceutical companies and Investors.
We understand the critical roles each segment performs in the hunt for new and better therapies. We also acknowledge the interdependency between them. We see ourselves at the “hub,” facilitating interaction between researchers, scientists, clinicians and financiers from the first experiment through clinical trials to market.
I’d like to learn more about how
Predictive Oncology can assist me with my role in
- Research
- Pharmaceuticals
- Investing

Academic Research and Predictive Oncology
Predictive Oncology gives academic researchers a head start on the uncertain path to drug discovery.
Our database of 150K+ clinically validated patient tumor histories and outcomes gives researchers an unprecedented amount of information to establish baselines and avoid duplicative effort.
Increased Success
We offer best chance for researchers to grow tumors in the lab
Results you can Trust
We provide stable, soluble proteins for reliable biophysical study
Actionable Data
Our tumor database combined with AI delivers actionable data for predictive treatment models
Faster to the finish
Predictive Oncology helps to shorten the time required to get a new drug from the lab to the market, and into the hands of clinicians for patient application.
Proven AI Software
Database, tumor modeling and AI combine to accelerate drug discovery timelines
Rapid analysis
Novel proprietary method to screen formulations and maintain protein solubility and stability
Lowered Cost, Shortened Timelines
Our novel and disruptive patient-centric approach allows for enhanced "speed-to-patient" for new therapies
A growing company in a growth market
Collectively, the companies of Predictive Oncology present an impressive array of critical data, products and services to meet the demands of researchers, developers, testers and clinicians.
Helomics has the tumor platforms, the lab, the access to patient outcomes and the AI to be a bona fide disruptor in drug discovery. Through our collaborative study with UPMC Magee Women’s Hospital, Predictive Oncology has demonstrated our ability to leverage the Helomics tumor data bank.
TumorGenesis has established an impressive international footprint with partners such as US Biological, the University of Alberta, Weill Cornell
Medicine, GLG Pharma and the Sylvester Center Center at the University of Miami Health System.
Soluble Biotech projects more than $2M in annual revenues through our solubility and stability products, testing capabilities and government grants.
Skyline Medical offers a self-contained waste fluid recovery and disposal system that enables safer, more efficient surgical procedures.
Few public companies offer the multi-omic capabilities of Predictive Oncology that allow us to serve a vital role at every stage of the drug discovery process, from the first lab experiment to the first clinical administration of a therapy.
Global Presence
Portfolio of subsidiaries provides international market presence and diversified approach
Valued Partnerships
Strategic partnerships with pharmaceutical, biopharmaceutical and diagnostic companies
Diversified Approach
Operates through four wholly owned subsidiaries, each with significant contributing assets